Other
Interest Expense, Nonoperating
Alnylam Pharmaceuticals Interest Expense, Nonoperating decreased by 36.8% to $69.29M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.8%, from $58.31M to $69.29M. Over 2 years (FY 2022 to FY 2025), Interest Expense, Nonoperating shows an upward trend with a 27.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementCash Flow Statement
SectionOther
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ1 2022
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase indicates higher debt levels or rising interest rates, which may increase financial risk.
Detailed definition
This represents the cost of servicing the company's debt obligations, excluding any interest income or capitalized inter...
Peer comparison
Standard across all industries; comparable to 'Interest Expense' on the income statement of any debt-financed company.
Metric ID:
other_interest_expense_nonoperatingHistorical Data
15 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $38.99M | $38.99M | $38.99M | $38.99M | $30.04M | $30.89M | $35.25M | $33.26M | $34.38M | $38.97M | $58.31M | $40.25M | $44.40M | $109.67M | $69.29M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -23.0% | +2.9% | +14.1% | -5.7% | +3.4% | +13.4% | +49.6% | -31.0% | +10.3% | +147.0% | -36.8% |
| YoY Change | — | — | — | — | -23.0% | -20.8% | — | +10.7% | +11.3% | — | +65.4% | +21.0% | +29.2% | +181.4% | +18.8% |
Range$30.04M – $109.67M
CAGR+17.9%
Avg YoY Growth+32.7%
Median YoY Growth+18.8%
Interest Expense, Nonoperating at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's interest expense, nonoperating?
- Alnylam Pharmaceuticals (ALNY) reported interest expense, nonoperating of $69.29M in Q1 2026.
- How has Alnylam Pharmaceuticals's interest expense, nonoperating changed year-over-year?
- Alnylam Pharmaceuticals's interest expense, nonoperating increased by 18.8% year-over-year, from $58.31M to $69.29M.
- What is the long-term trend for Alnylam Pharmaceuticals's interest expense, nonoperating?
- Over 2 years (2022 to 2025), Alnylam Pharmaceuticals's interest expense, nonoperating has grown at a 27.3% compound annual growth rate (CAGR), from $155.97M to $252.63M.
- What does interest expense, nonoperating mean?
- The cost of interest paid on outstanding debt.